The Role of the Stress Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using the Cortisol Synthesis Inhibitor Metyrapone in Healthy Adults

The purpose of this study is to determine the importance in the acute stress response induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes. Participants in this study will be given psilocybin in combination with a placebo or metyrapone, a cortisol synthesis inhibitor medication, on four different occasions.

开始日期2025-09-01

申办/合作机构

University of Calgary

NCT06556277

/ RecruitingN/A

Acute Consequences of Glucocorticoid Secretion in Overweight and Obese Individuals During Maximum Calorie Intake: a Double-blind, Randomized, Placebo-controlled, Cross-over Study

The investigator aim to understand whether food-induced glucocorticoids influence fat mass in overweight and obese people.
In a randomized, cross-over study, 23 overweight and obese volunteers will receive a block and replace therapy that mimics physiological glucocorticoid (GC) rhythm (metyrapone plus hydrocortisone) or placebo. Participants will undergo two identical overfeeding periods with each treatment. With the block and replace therapy food-induced GC peak will be suppressed. Metabolic and immunological parameters will be compared to reveal the effects of GCs during excessive overfeeding, particularly to understand changes in body fat.

开始日期2024-09-01

申办/合作机构-

NCT06106295

/ Recruiting临床2期IIT

Metyrapone Intervention in Patients With Mild Autonomous Cortisol Secretion (MACS)

The purpose of this study is to find out whether the study drug, metyrapone, is safe and effective in treating participants with Mild Autonomous Cortisol Secretion (MACS).

开始日期2023-12-19

申办/合作机构

Mayo Clinic

100 项与美替拉酮相关的临床结果

登录后查看更多信息

100 项与美替拉酮相关的转化医学

登录后查看更多信息

100 项与美替拉酮相关的专利（医药）

登录后查看更多信息

4,641

项与美替拉酮相关的文献（医药）

2025-04-21·CHEMICAL RESEARCH IN TOXICOLOGY

Systematic Investigation of CYP3A4 Using Side-by-Side Comparisons of Apo, Active Site, and Allosteric-Bound States

Article

作者: Mehra, Rukmankesh ; Shrivastava, Pranchal ; Mondal, Somnath ; Manhas, Anu ; Thakur, Shivani

Cytochrome P450 (CYP) 3A4 (CYP3A4) is a complex enzyme that metabolizes diverse substrates. It contains a large binding site accommodating diverse ligands, binding to active or allosteric sites. CYP3A4 does not always follow Michaelis-Menten kinetics. While K_m reflects substrate affinity, it does not necessarily determine the enzyme's activity, though it is often considered indicative of substrate binding characteristics. The mechanism may be highly sophisticated and driven by multiple factors. This suggests that the ligand binding affinity alone may not explain the differential behavior of the enzyme conformational stability. Here, we analyzed sequence conserveness of 57 CYPs, followed by a detailed molecular dynamics simulation study (9 μs) on CYP3A4. We studied three CYP3A4 enzyme states (apo-state, active-site, and allosteric-site ligand-bound states) collected from the same experimental setup to reduce the systematic error. We found that the enzyme conformational stability followed a consistent trend of allosteric > active > apo states, which was inconsistent with the enzyme-ligand (active/allosteric) binding affinity and the ligand conformational stability. However, the heme group showed a significant protein affinity and stability pattern directly related to the enzyme stability, suggesting that the active/allosteric binding may work by influencing the heme-CYP3A4 binding affinity, and the allosteric ligand appeared to form the most stable enzyme state of the three studied states.

2025-04-01·JOURNAL OF NEUROENDOCRINOLOGY

Corticotropin‐releasing hormone receptor 1 mediates the enhanced locomotor activity and metabolic demands to an acute thermal stress in adult zebrafish

Article

作者: Shvartsburd, Zachary ; Vijayan, Mathilakath M.

Abstract:

We recently showed that Crh‐Crhr1 signalling is essential for acute stress‐related locomotor activity in zebrafish larvae. However, the possibility that Crhr1 activation may also initiate the acute metabolic demands for stress coping was unexplored. Here, we tested the hypothesis that Crhr1 signalling is essential for the thermal stressor‐induced increases in the acute metabolic rate, a key response for coping with the enhanced energy demands during stress. We tested this by using a wildtype (WT) and a ubiquitous Crhr1 knockout (crhr1−/−) zebrafish and subjecting them to an acute thermal stressor (TS: +5°C above ambient for 60 min). The TS induced the heat shock proteins response in both genotypes, but the elevated cortisol response observed in the WT was absent in the crhr1−/− mutant. The TS also increased the locomotor activity and the metabolic rate in the WT fish, but this response was inhibited in the crhr1−/− mutants. To test if this was due to a lack of TS‐induced cortisol elevation in the crhr1−/− mutant, we mimicked the response in the WT fish by treating them with metyrapone, an 11β‐hydroxylase inhibitor. While metyrapone inhibited the TS‐induced cortisol elevation in the WT, it did not affect the metabolic rate. The lack of Crhr1 also reduced the swimming performance, and the lower Ucrit in the mutants corresponded with alterations in muscle energy metabolism. Together, our results indicate that Crh‐Crhr1 signalling, independent of downstream cortisol action, is essential for the TS‐induced acute hyperlocomotor activity and the associated increases in the metabolic demand for stress coping.

2025-03-28·Oxford Medical Case Reports

Ectopic ACTH-secreting pheochromocytoma without typical signs of Cushing syndrome

Article

作者: Mendoza-García, Jesús G ; Tenorio-Aguirre, Erika K ; Medina-Julio, David ; Soto-Montes, Zeltzin ; Solis-Coronado, Orlando D ; Martínez-Sánchez, Froylan D

Abstract:

This case report describes a 42-year-old female with a rare pheochromocytoma presenting without classic Cushingoid features but with uncontrolled hypertension, type 2 diabetes, and recurrent headaches. Despite the absence of typical signs, biochemical analysis revealed elevated cortisol and ACTH levels, and imaging showed a 6 cm adrenal mass. The patient was stabilized preoperatively with alpha-blockers and metyrapone before undergoing a successful laparoscopic adrenalectomy. Histopathology confirmed pheochromocytoma with aggressive features. Postoperatively, her blood pressure and symptoms improved, and her cortisol levels normalized. This case underscores the diagnostic challenges of ACTH-secreting pheochromocytomas without classic hypercortisolism signs and emphasizes the need for thorough endocrine and imaging assessments. Surgical resection remains the definitive treatment, with long-term follow-up essential to monitor for recurrence. This case contributes to the limited literature on the coexistence of pheochromocytoma and ectopic ACTH secretion.

项与美替拉酮相关的新闻（医药）

2025-05-15

·PRNewswire

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

The Cushing's disease pipeline possesses some drugs in mid and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including relacorilant, clofutriben, atumelnant, and others. The expected launch of these therapies shall further create a positive impact on the Cushing's disease market. LAS VEGAS, May 15, 2025 /PRNewswire/ -- DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. Key Takeaways from the Cushing's Disease Market Report According to DelveInsight's analysis, the market size for Cushing's disease was found to be USD 1 billion in the 7MM in 2024. In 2024, among all the current therapies for Cushing's disease, the highest revenue was generated by Mifepristone (KORLYM and generics) in the US. Based on DelveInsight's assessment in 2024, the 7MM had approximately 37K diagnosed prevalent cases of Cushing's disease. These cases are expected to rise due to advancements in diagnostic capabilities and increased awareness about the disease during the forecast period (2025–2034). Leading Cushing's disease companies developing emerging therapies, such as Corcept Therapeutics, Sparrow Pharmaceuticals, Crinetics Pharmaceuticals, H. Lundbeck, Stero Therapeutics, and others, are developing novel Cushing's disease drugs that can be available in the Cushing's disease market in the coming years. The promising Cushing's disease therapies in the pipeline include DUPIXENT (dupilumab), Linerixibat (GSK2330672), NEMLUVIO/MITCHGA (nemolizumab), Volixibat, and others. In March 2025, Corcept Therapeutics announced that the FDA had assigned a PDUFA target action date of December 30, 2025, for relacorilant to treat patients with endogenous hypercortisolism. In February 2025, Crinetics Pharmaceuticals mentioned that the company anticipates beginning enrollment for Atumelnant (CRN04894) in Phase Ib/IIa trials for Cushing's disease in late 2025 or early 2026. In October 2024, Sparrow Pharmaceuticals announced that clofutriben had been granted Orphan Drug Designation (ODD) by the US FDA for the treatment of endogenous Cushing's syndrome. Discover which therapies are expected to grab the major Cushing's disease market share @ Cushing's Disease Market Report Cushing's Disease Overview Cushing's disease is a rare but serious endocrine disorder caused by a pituitary tumor that triggers excessive cortisol production. It presents with a variety of symptoms such as weight gain, fatigue, mood disturbances, high blood pressure, and impaired glucose tolerance. Cushing's syndrome is responsible for 80–85% of hypercortisolism cases, with 75–80% of those linked to ACTH-producing pituitary adenomas. Without treatment, the 5-year survival rate is only about 50%, emphasizing the urgent need for effective therapies. Diagnosing Cushing's disease is especially difficult because it is rare, shares symptoms with other disorders, and presents in various ways. Only 40–60% of patients have a detectable tumor on standard Magnetic Resonance Imaging (MRI), and the diagnosis is often delayed by an average of 7 years. Cushing's Disease Epidemiology Segmentation The Cushing's disease epidemiology section provides insights into the historical and current Cushing's disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The Cushing's disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Cushing's Disease Total Diagnosed Prevalent Cases of Cushing's Disease Gender-Specific Diagnosed Prevalent Cases of Cushing's Disease Age-Specific Diagnosed Prevalent Cases of Cushing's Disease Cushing's Disease Treatment Market The primary treatment for Cushing's disease is usually transsphenoidal surgery to remove the pituitary tumor, which often leads to remission. However, some patients may experience a recurrence. When surgery is unsuccessful or not an option, medical therapies are used to control cortisol levels. Various medications are available for managing Cushing's disease, especially in cases where surgery is ineffective or not feasible. One such drug is KORLYM, developed by Corcept Therapeutics, approved for treating hyperglycemia in patients with Cushing's syndrome who also have Type 2 diabetes or glucose intolerance. In 2024, a generic version by Teva Pharmaceuticals entered the market, adding competition, and Corcept itself has released a generic version as well. Other approved options include S IGNIFOR and SIGNIFOR LAR, ISTURISA, and RECORLEV. In addition, off-label drugs like ketoconazole, metyrapone, cabergoline, mitotane, and etomidate are also used in the U.S., with some marketed in Europe by HRA Pharma. SIGNIFOR (pasireotide), developed by Recordati, was the first drug specifically approved for Cushing's disease by the FDA in 2012, and also gained EU approval. Recordati also markets SIGNIFOR LAR, a long-acting injectable version approved by the FDA and Japan's PMDA in 2018. This formulation, administered intramuscularly once every four weeks, shares the same mechanism as SIGNIFOR but offers a different delivery route. Recordati is recognized as a leading player in this therapeutic area. Another key product from the company is ISTURISA (osilodrostat), the first FDA-approved oral drug that inhibits cortisol production by targeting the enzyme 11β-hydroxylase (CYP11B1), which is involved in the final step of cortisol synthesis. Its oral administration makes it more convenient for patients compared to injectable therapies. ISTURISA is also being studied for pediatric use in an ongoing Phase II trial (NCT03708900). RECORLEV, originally developed by Strongbridge Biopharma and later acquired by Xeris Pharmaceuticals, was approved by the FDA in 2021. It is indicated for adults with endogenous Cushing's syndrome who are not surgical candidates or did not achieve a cure through surgery. Unlike ISTURISA, RECORLEV works by inhibiting cortisol production at multiple points in the steroidogenesis pathway, offering a distinct mechanism of action. To know more about Cushing's disease treatment guidelines, visit @ Cushing's Disease Management Cushing's Disease Pipeline Therapies and Key Companies Relacorilant (CORT125134): Corcept Therapeutics Clofutriben (SPI-62): Sparrow Pharmaceuticals Atumelnant (CRN04894): Crinetics Pharmaceuticals Lu AG13909: H. Lundbeck ST-002: Stero Therapeutics Discover more about Cushing's disease drugs in development @ Cushing's Disease Clinical Trials Cushing's Disease Market Dynamics The Cushing's disease market dynamics are expected to change in the coming years. Although Cushing's disease is generally considered a rare condition, growing awareness and recent advances in research suggest that diagnoses may rise in the future; despite a seemingly crowded market, many current hypercortisolism treatments fail to normalize cortisol levels effectively and pose significant side effects highlighting a substantial opportunity for innovation, especially given the limited therapies specifically targeting Cushing's disease and the potential of newer oral alternatives like ISTURISA and RECORLEV to offer greater flexibility compared to SC and intramuscular options such as SIGNIFOR and SIGNIFOR LAR. Furthermore, potential therapies are being investigated for the treatment of Cushing's disease, and it is safe to predict that the treatment space will significantly impact the Cushing's disease market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the Cushing's disease market in the 7MM. However, several factors may impede the growth of the Cushing's disease market. Due to non-specific guidelines and recommendations, patients with Cushing's disease often face suboptimal care, delayed diagnosis, and inconsistent treatment approaches, further compounded by the diagnostic complexity, frequent misdiagnosis, and symptom overlap with more common conditions, which leave many undiagnosed or untreated; while existing therapies such as ketoconazole and metyrapone approved in Europe based on limited retrospective data and used off-label in the US despite high costs are widely trusted and entrenched in clinical practice, posing a significant barrier to the adoption of emerging therapies. Moreover, Cushing's disease treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the Cushing's disease market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the Cushing's disease market growth. Scope of the Cushing's Disease Market Report Therapeutic Assessment: Cushing's Disease current marketed and emerging therapies Cushing's Disease Market Dynamics: Key Market Forecast Assumptions of Emerging Cushing's Disease Drugs and Market Outlook Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Cushing's Disease Market Access and Reimbursement Download the report to understand which factors are driving Cushing's disease market trends @ Cushing's Disease Market Trends Table of Contents Related Reports Cushing's Syndrome Market Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Cushing's Syndrome Pipeline Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Cyclacel Pharmaceuticals, Sparrow Pharmaceuticals, Stero Therapeutics, among others. Endogenous Cushing's Syndrome Market Endogenous Cushing's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endogenous Cushing's syndrome companies including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. Endogenous Cushing's Syndrome Pipeline Endogenous Cushing's Syndrome Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endogenous Cushing's syndrome companies, including Corcept Therapeutics, Crinetics Pharmaceuticals, Sparrow Pharmaceuticals, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准孤儿药临床2期

2024-09-14

·米内网

10年官司，医药股一哥“败”了！知名药企1元甩卖子公司，59个中成药或生变，国药厉害了

看点 view 本周，国家医保局提及第十批集采，三甲医院原书记落马；药品市场迎变局，大批中药纳入医保，59个品种带量采购，83个药品降价了；研发新进展，首个国产IL-4Rα抗体获批，2款中药1类新药亮相，15个儿童药鼓励研发；企业大新闻，知名药企1元甩卖子公司，国药、上药等上榜中国企业500强……医药行业一周大事件，精彩不容错过！米内一周TOP榜米内数据550亿！第十批集采58个超“卷”品种备战18个独家中成药丸剂厉害了！31亿品种领跑药企动态医药股“一哥”近50亿现金分红太惊人华海药业大丰收！16个新产品获批华润双鹤发威了！拿下17个重磅品种审评药闻中药1类新药来袭！110亿市场波澜再起齐鲁拿下暴涨990%降脂药正大天晴1类新药来袭，抢攻280亿市场15亿注射剂，浙江医药过评了国家医保局再次提及第十批集采本周，国新办举行多场“推动高质量发展”系列主题新闻发布会。9月10日，国家医保局就下一步集采方向、医保基金监管、全国统一医保信息平台运用、医保支付方式改革等热点问题作出回应，提到要持续扩大集采覆盖面，开展新批次国家组织药品集采和高值医用耗材集采。9月13日，国家药监局局长李利介绍：今年1至8月，国家药监局批准创新药品31个、创新医疗器械46个，比去年同期分别增长19.23%和12.16%；国家药品抽检共计20969批次，合格率为99.43%，药品安全形势保持总体稳定等。（米内网整理）大批中药纳入医保 9月9日，河南省医保局发布《关于印发<河南省基本医疗保险、工伤保险和生育保险医疗机构制剂和中药饮片目录（2023年）的通知》（以下简称目录）。《目录》共对医保药品进行了三个方面的“扩容”：1、将188个符合条件的医疗机构制剂纳入省医保基金支付范围，并确定了全省统一的支付标准；2、将24种中药饮片新增纳入《目录》，按甲类药品管理；3、将397种中药配方颗粒纳入基金支付范围，按乙类药品管理。（河南省医保局） 59个品种！医药大省集采来袭 9月11日，浙江省医保局发布《浙江省公立医疗机构第五批药品集中带量采购公告》，此次集采覆盖34个化药、25个中成药，共计59个品种。化药、中成药分别开展评审，采购周期24个月。（浙江省医保局）米内数据： 34个化药中，奥司他韦颗粒剂、哌拉西林注射剂、腹膜透析液注射剂、低钙腹膜透析液注射剂等2023年在中国公立医疗机构终端的销售额均超过20亿元。 11个独家品种在列！35个中成药拟集采 9月9日，安徽省医药集中采购平台发布通知，就《安徽省2024年度中成药集中带量采购文件(征求意见稿)》征求意见。此次集采拟纳入18个产品组、35个中成药（11个为独家品种），采取“价格指标+技术指标”计算申报企业综合得分，即企业综合得分=价格指标得分+技术指标得分，最多可以有7家企业拟中选。（米内网整理）最高降幅98%！83个药品降价了 9月9日，四川省药械招标采购服务中心发布通知，公示部分药品降价信息。根据企业提交的申请，拟调低83个药品（以序号计）的联动参考价格，其中广西鸿博原生制药的抗菌消炎片、夏桑菊颗粒、六味地黄胶囊、益母草颗粒降幅均超过90%。（米内网整理）剔除8个！15个儿童药鼓励研发 9月9日，国家卫健委发布通知，第五批鼓励研发申报儿童药品清单出炉，共有15个药品在列，覆盖全身用抗感染药、呼吸系统用药、抗肿瘤及免疫调节剂等治疗领域。与之前（5月30）公示的建议清单相比，删除了西替利嗪、甲苯磺酸托氟沙星、美替拉酮、匹莫齐特、培维索孟、阿昔单抗、瑞斯利珠单抗、艾哌依卡基等8个品种。（医药云端）延伸阅读：此前，国家卫健委同有关部门，已先后制定并发布了四批含129种药品的《鼓励研发申报儿童药品清单》，其中有30个药品已获批上市，覆盖神经系统用药、消化道和新陈代谢用药、心血管系统用药等8个治疗领域，其中有15个是罕见病用药。 2款中药1类新药亮相！4100亿市场掀热潮本周，2款中药1类新药提交临床申请获受理，为四川省中医药科学院的金蚕颗粒、广州医科大学附属市八医院的芩葛退热解毒颗粒。今年以来，已有9款中药1类新药提交NDA，目前还在审评审批中；34款中药1类新药（不含原料药）提交IND，其中有21款已获批临床。（米内网整理）米内数据：近年来中国三大终端六大市场（统计范围详见本文末）中成药销售额逐年上涨，2023年超过4100亿元，同比增长6.5%。首个国产IL-4Rα抗体获批上市 9月12日，康诺亚公告称，公司自主研发的1类新药司普奇拜单抗注射液（商品名：康悦达）正式获得国家药监局批准上市，用于治疗成人中重度特应性皮炎。作为国内首个、全球第二个申报并获批上市的IL-4Rα抗体药物，康悦达的上市，填补了国产特应性皮炎生物制剂领域的空白。（公司公告） 10年专利纠纷！迈瑞医疗一项专利被裁定全部无效迈瑞医疗和科曼医疗缠斗了十年的专利纠纷，出现了新进展。近日，据国家知识产权局公告显示，裁定迈瑞医疗“流量传感器及流量传感器安装组件”的实用新型专利ZL200720170903.X，因不具备创造性，而宣告专利权全部无效。（氨基观察）案件回顾： 2014年4月，迈瑞医疗以科曼医疗侵犯其专利为由向深圳市中级人民法院发起诉讼，并以厂房为担保，申请对科曼银行账户进行冻结。很快，法院作出判决：被告科曼医疗侵权。不过，科曼医疗没有妥协，而是发起反击，几个月后向国家知识产权局针对迈瑞这件专利进行无效宣告请求。在过去10年的漫长时间里，两家公司在法庭上多次交锋，各有过胜负。这一次的裁决，意味着科曼医疗扳回了一局，双方对该专利权争夺战暂告一段落。转让价1元！知名药企出售子公司多年前9亿元拿下的子公司，亚太药业如今以1元对外卖出“善后”。9月10日，亚太药业公告称，公司与宁波和依文化传媒签署了股权转让协议，将公司持有的上海新高峰生物医药100%股权转让给和依文化。由于上海新高峰目前净资产为负，故本次股权转让价格为1元。与此同时，亚太药业将豁免上海新高峰的债务。（界面新闻）业内观点：随着医药市场环境的改变，药企为了更持续的发展正在加快做“加减法”。国药、上药......上榜中国企业500强 9月11日，在2024中国500强企业高峰论坛上，中国企业联合会、中国企业家协会连续第23次向社会发布了“中国企业500强”榜单。500强入围门槛达到473.81亿元，较去年提升3.83亿元，实现22连升。有8家医药企业上榜，分别为中国医药集团、上海医药集团、广州医药集团、复星国际、重药控股、重庆智飞生物、深圳海王集团、石药控股集团，其中中国医药集团位列第33名，为唯一进入TOP100的药企。（蒲公英Ouryao）涉及收受贿赂！三甲医院原书记落马 9月10日，黑龙江省纪委监委通报6起违反中央八项规定精神典型问题，其中牡丹江市第二人民医院党委原书记程刚违规操办岳母、父亲葬礼，子女升学等事宜，收受礼金共计33万余元，此外还存在其他严重违纪违法问题，受到开除党籍、开除公职处分，涉嫌犯罪问题移送检察机关依法审查起诉。（黑龙江省纪委监委）注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

带量采购

2024-07-10

·esteve.com

ESTEVE ACQUIRES HRA PHARMA RARE DISEASES

ESTEVE has completed the acquisition of HRA Pharma Rare Diseases, a business specialized in rare diseases, from Perrigo Company plc. With this acquisition, ESTEVE expands its portfolio in rare and severe diseases adding, to the current existing offer, three new medications to treat Cushing's syndrome and adrenocortical carcinoma: Metopirone, Lysodren, and Ketoconazole HRA. HRA Pharma Rare Diseases has been a leading company for over 15 years in rare and severe diseases, providing the best care and services to individuals living with rare diseases, and is committed to supporting healthcare professionals worldwide. "This acquisition allows us to accelerate our international expansion, strengthening our global presence and ability to better address unmet needs, thus improving the lives of more people," highlights Staffan Schüberg, Chief Executive Officer of ESTEVE. With annual net revenues in 2023 of approximately 50 million euros, HRA Pharma Rare Diseases has a presence in numerous European countries and the United States with a team of 49 individuals. This agreement represents an investment of up to 275 million euros, structured with an initial fixed contribution and future variable payments tied to revenue. Share

并购

100 项与美替拉酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00410	美替拉酮	V04CD01	DB01011

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
肾上腺皮质功能不全	-	Novartis AG	2014-05-30
库欣综合征	澳大利亚	CHIESI Farmaceutici SpA	1991-08-02
垂体ACTH分泌过多	美国	HRA Pharma Rare Diseases SAS	1961-12-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
内源性库欣综合征	临床3期	比利时	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	德国	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	匈牙利	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	意大利	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	波兰	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	罗马尼亚	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	西班牙	HRA Pharma Development SARL	2015-04-01
内源性库欣综合征	临床3期	土耳其	HRA Pharma Development SARL	2015-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06106295 (MACS, ENDO2024)	临床2期	cortisol \| ACTH \| DHEAS	30	Metyrapone 250 mg	齋餘簾簾願繭衊壓顧襯(憲網膚衊蓋選艱鏇選壓) = 遞壓遞糧簾遞網壓窪齋鑰膚製鏇網膚壓簾遞夢 (糧獵觸鹹膚夢鹹衊廠艱, 25 ~ 34) 更多	-	2024-06-01
MACS (ENDO2024)	N/A	-	15	Metyrapone 250mg-500mg at 6pm and 250mg at 10pm	齋淵艱獵壓獵夢餘繭夢(廠鏇繭淵網襯網鹽製衊) = 糧壓膚壓壓夢夢選艱衊憲顧糧遞顧淵糧鹹艱觸 (鏇窪觸繭範餘鏇憲餘顧, 5.5) 更多	积极	2024-06-01
LBSAT59 (ENDO2022)	N/A	ACTH \| cortisol \| DHEAS	22	Metyrapone (Patients with OIAI)	遞觸簾艱顧範襯製繭觸(觸積築願選網膚窪襯繭) = 築襯襯築鏇鏇鹽糧簾糧蓋廠鑰簾壓鹽壓顧蓋遞 (顧製蓋衊糧憲製廠襯艱, 8.1 ~ 51) 更多	-	2022-11-01
LBSAT59 (ENDO2022)	N/A	ACTH \| cortisol \| DHEAS	22	Metyrapone (Patients without OIAI)	遞觸簾艱顧範襯製繭觸(觸積築願選網膚窪襯繭) = 觸鏇觸鬱膚夢繭餘構繭蓋廠鑰簾壓鹽壓顧蓋遞 (顧製蓋衊糧憲製廠襯艱, 5.9 ~ 55) 更多	-	2022-11-01
NCT02297945 (PROMPT, ENDO2021)	临床3期	内源性库欣综合征 24 hours urine free cortisol (UFC)	50	Metyrapone	積鬱醖鏇選鏇選簾遞鏇(選築遞觸願願膚廠窪糧) = 蓋願廠窪鏇築築觸醖選網願鑰醖範獵觸遞觸壓 (獵鬱鬱願襯鏇憲蓋繭壓, 291 ~ 8476) 更多	积极	2021-05-03
ENDO2021	N/A	库欣综合征 AM serum cortisol \| PM serum cortisol \| ACTH ... 更多	-	Metyrapone	鹽糧築廠糧構鹹積積淵(製製遞壓範艱簾淵範觸) = 鹽襯衊遞廠鹽遞觸遞淵鹹餘憲遞繭鹹觸襯窪餘 (選鹽製願蓋艱廠繭醖鹽 ) 更多	积极	2021-05-03
MON-905 (ENDO2020)	N/A	垂体ACTH分泌过多	-	Metyrapone 1,000 mg/day	鹽願廠構鹽蓋網艱糧簾(繭鹹積鹽餘遞艱齋鏇選) = 鏇顧淵艱製鑰廠鹹願選築壓憲醖廠襯範鏇範艱 (襯鹽夢觸構鏇顧繭獵襯 ) 更多	积极	2020-05-08
MON-905 (ENDO2020)	N/A	垂体ACTH分泌过多	-	Dexamethasone 0.1-10 nM	選簾廠網鏇鑰遞廠遞築(製積獵願糧築構簾夢鏇) = 衊獵廠製糧簾糧製繭淵範顧觸遞壓築鹽醖製壓 (鹽積醖簾憲鹹選襯憲廠 ) 更多	积极	2020-05-08
SUN-LB068 (ENDO2019)	N/A	神经内分泌肿瘤 \| 异位ACTH综合征	-	Metyrapone	窪憲製窪獵鹽遞廠鏇網(艱製糧蓋蓋壓遞襯襯蓋) = 壓鏇築鹽鑰選觸廠醖遞壓齋選遞積簾窪淵壓憲 (鏇鏇淵鹹製齋齋齋壓觸 ) 更多	积极	2019-04-30
SAT-446 (ENDO2019)	N/A	普拉德-威利综合症	45	Metyrapone (Adults with Prader-Willi Syndrome)	糧願鏇膚蓋糧選簾鬱膚(遞築鑰顧壓簾鹹網艱築) = 蓋築獵選鏇窪壓簾遞構網蓋壓鹽獵衊製獵遞壓 (構築繭蓋鏇艱鑰鏇齋襯 )	积极	2019-04-30
ESPE2016	N/A	库欣综合征	-	Metyrapone	網窪壓積製壓鹽製願餘(願觸壓鹹獵齋膚選艱壓) = 襯顧淵廠鑰鏇顧淵廠遞築膚衊蓋艱齋衊積鑰淵 (襯選選範獵範選膚鹹鏇 )	-	2016-09-10
Pubmed \| J Clin Endocrinol Metab	N/A	库欣综合征	195	Metyrapone	鹹顧鹹鑰襯壓窪獵觸願(蓋鬱製製簾夢衊繭窪齋) = 觸鹽鹹觸範齋齋鹹鹹積鏇觸網襯築鏇淵鑰選淵 (製淵鏇鬱鹽艱構範願餘 ) 更多	积极	2015-11-01